Transfusion medicine

Recent Updates

May 31, 2017
Chapter 16

This chapter focuses on preoperative autologous donation (PAD). There are other types of autologous blood use (e.g. acute normovolemic hemodilution and intraoperative and postoperative blood salvage) which are not discussed in this chapter.

PAD refers to the donation of blood by a patient for his/her own future use; generally this is for a scheduled elective surgery. The top three procedures associated with a request for a PAD are total hip replacement, total knee replacement and hysterectomy.

In most cases, allogeneic blood transfusions are a safe and available option. Autologous and directed donations should be confined to circumstances of rare blood types or plasma protein deficiencies in which  allogeneic units may not meet patient needs. Rare blood types represent only a small number of autologous units collected each year. See Chapter 13 of this Guide for more information on directed donations.

Sep 8, 2017
Chapter 8

Pre-transfusion testing refers to the laboratory testing required to ensure compatibility between the blood of the transfusion recipient and the blood product intended for transfusion. This process includes proper completion of the requisition, proper patient identification, collection and labelling of the blood sample from the patient, laboratory testing to determine the patient’s blood group and to identify the presence of red blood cell alloantibodies, and compatibility testing. Pre-transfusion testing is completed when a compatible blood product is identified for transfusion to the intended recipient. This chapter provides an overview of the pre-transfusion tests that are routinely performed.

Mar 22, 2017
Chapter 6

All blood transfused in Canada is collected from volunteer donors. To ensure the safety of the blood products, donors are carefully screened against an extended list of eligibility criteria and their donated blood products are tested for transfusion-transmissible diseases. Donor eligibility criteria also reduce potential health risks for the donor. This chapter describes the donor selection process, the pathogen testing done on blood products, and the pathogen inactivation processes that can further reduce the potential risk of transfusion-transmitted diseases.


Upcoming Events

June 2, 2018 | 8:00AM to June 7, 2018 | 5:00PM


Check out the CSTM website and the ISBT website  for more information.

Stem Cells


Modified on: 
Dec 15, 2017

New data released this week by Canadian Blood Services and the Canadian Institute for Health Information sheds light on organ donation and transplantation system progress


Close to 3000 lifesaving transplants were performed in Canada in 2016 of which 758 donations came from deceased donors, and 545 from living donors, according to the latest numbers released by the Canadian Institute for Health Information (CIHI) and Canadian Blood Services.

Dr. Earl W. Davie, Dr. Ross T. MacGillivray and Dr. Edmond H. Fischer at the 2017 Symposium in Vancouver.

Modified on: 
Dec 6, 2017

Drs. Earl W. Davie, Ross T. MacGillivray and Edmond H. Fischer at the 2017 Earl W. Davie Symposium Vancouver. Read all about this years event and find out more about the inspiration behind it.

lab work

Modified on: 
Nov 29, 2017

If you’re already a subscriber to our Research and Education Round Up, thank you! You’re one of almost 700 readers interested in the latest transfusion and transplantation news, publications and events from Canadian Blood Services’ Medical Services and Innovation research and education network. If you already know the value of the Round Up, please tell your colleagues. They just might thank you.